Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/141529
Title: | Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis |
Author: | Fabregat Romero, Isabel Caballero Díaz, Daniel |
Keywords: | Càncer Cèl·lules hepàtiques Fetge Plasticitat Cancer Liver cells Liver Plasticity |
Issue Date: | 10-Sep-2018 |
Publisher: | Frontiers Media |
Abstract: | The Transforming Growth Factor-beta (TGF-β) family plays relevant roles in the regulation of different cellular processes that are essential for tissue and organ homeostasis. In the case of the liver, TGF-β signaling participates in different stages of disease progression, from initial liver injury toward fibrosis, cirrhosis and cancer. When a chronic injury takes place, mobilization of lymphocytes and other inflammatory cells occur, thus setting the stage for persistence of an inflammatory response. Macrophages produce profibrotic mediators, among them, TGF-β, which is responsible for activation -transdifferentiation- of quiescent hepatic stellate cells (HSC) to a myofibroblast (MFB) phenotype. MFBs are the principal source of extracellular matrix protein (ECM) accumulation and prominent mediators of fibrogenesis. TGF-β also mediates an epithelial-mesenchymal transition (EMT) process in hepatocytes that may contribute, directly or indirectly, to increase the MFB population. In hepatocarcinogenesis, TGF-β plays a dual role, behaving as a suppressor factor at early stages, but contributing to later tumor progression, once cells escape from its cytostatic effects. As part of its potential pro-tumorigenic actions, TGF-β induces EMT in liver tumor cells, which increases its pro-migratory and invasive potential. In parallel, TGF-β also induces changes in tumor cell plasticity, conferring properties of a migratory tumor initiating cell (TIC). The main aim of this review is to shed light about the pleiotropic actions of TGF-β that explain its effects on the different liver cell populations. The cross-talk with other signaling pathways that contribute to TGF-β effects, in particular the Epidermal Growth Factor Receptor (EGFR), will be presented. Finally, we will discuss the rationale for targeting the TGF-β pathway in liver pathologies. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2018.00357 |
It is part of: | Frontiers in Oncology, 2018, vol. 8, p. 357 |
URI: | http://hdl.handle.net/2445/141529 |
Related resource: | https://doi.org/10.3389/fonc.2018.00357 |
ISSN: | 2234-943X |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
688164.pdf | 2.26 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License